Durvalumab (ICI targeting PD-L1) with tremelimumab (a human monoclonal antibody against CTLA-4) was observed to improve the OS and the PFS in patients with metastatic NSCLC and PD-L1 expression lower than 25% (ARTIC trial) [222]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.